Newton, Massachusetts, US — October 30, 2026
Acumen Pharmaceuticals, Inc. announced that its Phase 2 ALTITUDE-AD clinical trial of sabirnetug (ACU193) did not meet its primary endpoint in participants with early Alzheimer’s disease. The study failed to demonstrate a statistically significant improvement in cognitive and functional outcomes at 18 months compared with placebo at either the 35 mg/kg or 50 mg/kg dose. Key secondary efficacy endpoints, including the Clinical Dementia Rating–Sum of Boxes (CDR-SB), also did not achieve statistical significance, with no meaningful difference reported between either treatment group and placebo. Sabirnetug was generally well tolerated, and amyloid-related imaging abnormalities–edema (ARIA-E) were observed in approximately 10% of treated participants. Although positron emission tomography (PET) assessments showed statistically significant reductions in amyloid plaque load at Weeks 36 and 76 for both dose groups, these imaging findings did not translate into demonstrated clinical benefit on the trial’s primary or key secondary endpoints. Following the topline results, Acumen plans to discontinue sabirnetug development, including the ALTITUDE-AD open-label extension, and focus on cash conservation and strategic alternatives.
ALTITUDE-AD Trial Design and Topline Findings
Initiated in 2024, ALTITUDE-AD (NCT06335173) was a Phase 2, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate whether sabirnetug could slow cognitive and functional decline in people with early Alzheimer’s disease. The trial enrolled 542 participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease across investigative sites in the United States, Canada, the European Union and the United Kingdom. Participants received intravenous sabirnetug infusions once every four weeks or placebo. The primary endpoint measured change from baseline in cognitive and functional decline using the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months. Neither the 35 mg/kg nor the 50 mg/kg treatment group achieved a statistically significant improvement compared with placebo. The key secondary endpoint, CDR-SB, also failed to show statistical significance. Acumen reported that additional data, including fluid biomarkers and further imaging assessments, are expected in the coming weeks. However, the company does not expect these analyses to change the overall efficacy conclusions. The results highlight the distinction between reducing a biological marker, such as amyloid plaque burden, and demonstrating measurable benefits in patients’ cognition and daily functioning.
Sabirnetug’s Mechanism and Safety Profile
Sabirnetug (ACU193) is a humanized monoclonal antibody designed to selectively target soluble amyloid beta oligomers (AβOs) rather than amyloid beta monomers or deposited amyloid plaques. Soluble AβOs are considered potentially toxic forms of amyloid beta that can bind to neurons, interfere with synaptic function and contribute to neurodegeneration. Acumen developed sabirnetug around the hypothesis that targeting these soluble oligomers could address an early and persistent contributor to Alzheimer’s disease pathology. The investigational antibody previously received Fast Track designation from the US Food and Drug Administration for early Alzheimer’s disease and advanced into Phase 2 following Phase 1 evaluation in the INTERCEPT-AD study. In ALTITUDE-AD, the treatment was generally well tolerated, with ARIA-E reported in approximately 10% of sabirnetug-treated participants. Despite the statistically significant reductions in amyloid plaque load observed through PET imaging at both dose levels, the trial did not demonstrate corresponding improvements in clinical efficacy measures. The outcome therefore does not establish clinical benefit from sabirnetug in early Alzheimer’s disease. Acumen said the additional biomarker and imaging analyses will provide further information, although they are not expected to alter the decision to stop development.
Advertisement
Development Discontinuation and Strategic Priorities
Based on the topline findings, Acumen intends to cease clinical development of sabirnetug, including the open-label extension of ALTITUDE-AD. The company also plans to implement cash conservation measures and explore strategic options intended to maximize shareholder value. These options will include consideration of its Enhanced Brain Delivery (EBD®) program, which is being developed to improve therapeutic delivery across the blood-brain barrier. Acumen is collaborating with JCR Pharmaceuticals on an EBD approach using transferrin-receptor-targeting technology and is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s ENHANZE® drug delivery technology. However, the discontinuation decision applies to the sabirnetug clinical program following the Phase 2 efficacy results, and the company has not announced specific outcomes for its broader strategic review. Chief Executive Officer Daniel O’Connell expressed appreciation to the patients, caregivers, investigators, clinical trial sites and employees involved in the program. Acumen is headquartered in Newton, Massachusetts, and focuses on developing therapies targeting toxic soluble amyloid beta oligomers for Alzheimer’s disease. The ALTITUDE-AD outcome marks a significant setback for its lead clinical candidate and shifts attention to the company’s remaining technology and strategic options.
Source:Acumen Pharmaceuticals,, Press release
